pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Aug 27·1 min read
save

Former Stanford president posts emails to counter fraud claims in new book

Aug 27, 2026·read at STAT ↗Negative

Former Stanford president Marc Tessier-Lavigne has posted a more than 3,000-word response on his lab website, including emails with former colleagues, to dispute claims that he fabricated research results.

The claims were raised in Theo Baker’s book "How to Rule the World," which portrays Tessier-Lavigne as a case of scientific misconduct related to a 2009 neurodegeneration paper published while he was at Genentech.

In his rebuttal, Tessier-Lavigne argues the study was valid and uses the released correspondence to support his defense, seeking to restore his reputation after a misconduct investigation led to his resignation as Stanford’s president.

The episode has renewed attention on research integrity issues within academic-industry collaborations in the biotech sector.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Former Stanford president releases emails to rebut fraud and cover-up allegations in new book”

read at STAT ↗
471 words · retrieved Aug 27
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
GENENTECH2
topics
Obesity

related stories

  • 4d agoRoche drops muscle-sparing obesity antibody after flunked interim analysisFierce Biotech
  • Sep 24Roche inks up to $2B deal with Atavistik for new cardiometabolic drugsBioSpace
  • Sep 1Roche finds another oncology gem in Asia with $1.5B B cell disease partnershipBioSpace
  • Aug 28Genentech strikes second Asia deal in a week, betting up to $1B in oncology ADC alliance with DualityBioBioSpace
  • Aug 28Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical dataFierce Biotech